Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation

The aim of the trial was to assess whether extending plasma levels of the alpha7-nicotinic acetylcholine receptor (nAChR) agonist 3-(2,4-dimethoxybenzylidene)-anabaseine (DMXB-A) over time enhances its cognitive effects in schizophrenia. Both smoking and non-smoking patients were studied, to determi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuropsychopharmacology
Auteurs principaux: Kem, William R, Olincy, Ann, Johnson, Lynn, Harris, Josette, Wagner, Brandie D, Buchanan, Robert W, Christians, Uwe, Freedman, Robert
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2018
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5770760/
https://ncbi.nlm.nih.gov/pubmed/28825423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/npp.2017.182
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires